Month: January 2026

In the treatment pathway of prostate cancer, biochemical recurrence (BCR) represents a critical turning point. Especially for high-risk BCR patients with a short PSA doubling time, how to delay disease progression and improve overall survival (OS) has long been a major clinical concern. At the recent 15th Shanghai Urological Oncology Academic Conference, Oncology Frontier – UroStream invited Professor Stephen J. Freedland from Cedars-Sinai Medical Center to provide an in-depth interpretation of the EMBARK study, including its study rationale, clinical benefits, and individualized treatment strategies for high-risk BCR patients.

For many years, adjuvant therapy for renal cell carcinoma (RCC) remained in a state of “therapeutic vacuum.” RCC is intrinsically resistant to radiotherapy and chemotherapy, and early attempts to introduce targeted therapies into the adjuvant setting failed to deliver meaningful benefits. The success of the KEYNOTE-564 trial has been a turning point—ushering RCC adjuvant therapy into the era of immunotherapy and redefining postoperative management for high-risk patients.

In the era of precision medicine for prostate cancer, individualized clinical decision-making has become a central focus of daily practice. At a recent academic conference on urologic oncology, Professor Hailiang Zhang from Huadong Hospital affiliated with Fudan University shared his clinical perspectives on novel hormonal therapy (NHT) in metastatic prostate cancer. He emphasized that, based on solid evidence from randomized clinical trials, NHT combined with androgen deprivation therapy (ADT) has become the standard first-line treatment for both metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC). Nevertheless, optimal treatment selection requires an integrated assessment of tumor burden, genomic characteristics, patient age, and comorbidities, enabling a truly “tailor-made” approach.

At a recent academic conference on urologic oncology, Professor Jun Guo from Peking University Cancer Hospital & Institute delivered an important presentation systematically reviewing the ten-year journey of Chinese researchers in the field of drug therapy for urothelial carcinoma (UC)—from following international trends to taking a leading role. His lecture focused on the landmark achievements of China-originated antibody–drug conjugates (ADCs), represented by disitamab vedotin (RC48), particularly when combined with immunotherapy. Based on Professor Guo’s presentation, this article aims to showcase the international leap achieved by Chinese research in urologic oncology.

In 2025, the 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai. The meeting convened leading experts in urologic oncology from across China to discuss cutting-edge diagnostic and therapeutic strategies for genitourinary malignancies, including prostate cancer, renal cell carcinoma, and bladder cancer. During the conference, Professor Jingjing Wang, representing the field of medical oncology, delivered an outstanding presentation grounded in the latest evidence-based data, focusing on precision treatment strategies for metastatic castration-resistant prostate cancer (mCRPC), with particular emphasis on combination regimens involving PARP inhibitors. Based on Professor Wang’s presentation, this article systematically reviews the therapeutic challenges of mCRPC, genetic screening strategies, and the clinical benefits of emerging combination approaches, with the aim of providing practical insights for clinicians.

From November 10–16, 2025, the 9th West China Urologic Oncology Tianfu Academic Conference and the 11th Academic Conference on Urologic and Male Genitourinary Tumors of the Sichuan Anti-Cancer Association were grandly held in Chengdu. The meeting brought together leading experts in urologic oncology from China and abroad, providing a high-level platform for academic exchange. During the conference, Professor Yao Zhu from Fudan University Shanghai Cancer Center delivered a compelling lecture entitled “Evaluation of Immunotherapy in Prostate Cancer”. His presentation offered a critical analysis of the successes and failures of clinical research in this field over the past decade and provided forward-looking insights into future precision treatment strategies. This article is a comprehensive synthesis of Professor Zhu’s presentation.

Editor’s Note: The 15th Shanghai Urologic Oncology Academic Conference was grandly held in Pudong, Shanghai, bringing together leading experts in urologic oncology from China and abroad. The meeting focused on bladder-sparing strategies for non–muscle-invasive bladder cancer (NMIBC), advances in novel intravesical agents, and the latest developments in immunotherapy. At the conference, Professor Xiaolin Lu from Fudan University Shanghai Cancer Center delivered a dedicated presentation from the perspective of intravesical therapy, systematically outlining the challenges in NMIBC management. He highlighted groundbreaking clinical trial results from the Fudan Cancer Center team on novel intravesical agents—particularly interleukin-15 (IL-15) and its fusion proteins, modified chemotherapeutic formulations, and oncolytic viruses—painting a new blueprint for the future treatment of NMIBC.

Editor’s Note: Prostate cancer is one of the most common malignancies in men. While prostate-specific antigen (PSA) monitoring remains a cornerstone for the early detection of biochemical recurrence (BCR), advances…